AI Pathology Diagnostics Platform

Title

AI Pathology Diagnostics Platform

Content

The following is a guest article by Razik Yousfi, CEO and CTO at Paige (paige.ai) As AI gains traction in healthcare, it is demonstrating enormous potential to transform cancer diagnostics and serve as a powerful partner to pathologists—many of whom have been using glass slides and microscopes for over 150 years. Paige is recognized for its industry-leading AI technology, regulatory approvals, and development of the largest foundation models in pathology, built upon one of the world's most comprehensive databases originating from a world-renowned cancer center. As one of the first to bring novel AI technology and integrated diagnostics into clinical pathology, Paige is shaping the future of cancer detection. Paige pioneered AI-driven pathology solutions, receiving the first-ever FDA approval for its AI-powered cancer detection tool in 2021, and has since expanded its suite of models to detect cancer across 40+ organs and tissue types, including common, rare, and precursor lesions. Its partnerships with leading commercial labs, digital pathology providers, and healthcare institutions are accelerating AI adoption worldwide. Paige's PanCancer Suite, developed using Paige Virchow V2, one of Paige's state-of-the-art foundation models trained on 3 million digitized slides and 1.8 billion parameters, recently demonstrated clinical grade ability to help pathologists detect cancer in more than 40 tissue and organ types, including the most subtle complexities of common, rare, and precancerous regions. It prioritizes cases, flags critical findings, and serves as a quality control tool to ensure no cancer was missed before signing off. Another example, Paige OmniScreen is extremely promising for its ability to simultaneously screen 1600 molecular biomarkers without needing to re-biopsy patients, providing insights from routine H&E-stained digital pathology slides into the genomic makeup and profile of cancer. OmniScreen recognizes key mutations and pathways critical to cancer progression. This helps pharmaceutical companies develop new drugs targeting genomic signals. The capabilities of Paige's Virchow Foundation Models were highlighted in a recent publication in Nature Medicine. Paige's latest foundation models were trained on de-identified data from more than 225,000 patients, representing a broad spectrum of gender, race, ethnicity, and geographic diversity. This diversity ensures that the technology is generalizable and equitable, reducing disparities in diagnosis and meeting the highest regulatory standards for ethical AI in healthcare.